公开(公告)号：US20190194346A1

公开(公告)日：2019-06-27

申请号：US15778759

申请日：2016-11-24

Applicant: Synthon Biopharmaceuticals B.V.

Inventor： Miranda Maria Cornelia VAN DER LEE ,  Gerardus Joseph Andreas ARIAANS ,  Jan SCHOUTEN ,  Marion BLOMENROHR ,  Patrick Gerhard GROOTHUIS ,  Rudy Gerardus Elisabeth COUMANS

IPC: C07K16/32 ,  A61P35/00 ,  A61K31/437 ,  A61K47/54 ,  A61K47/60 ,  A61K47/68 ,  C07K16/30

CPC classification number: C07K16/32 ,  A61K31/437 ,  A61K39/44 ,  A61K45/06 ,  A61K47/546 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/92

Abstract: The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.